MedTrace Logo

Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

NCT04462263 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-07-07

No results posted yet for this study

Summary

A Study in Healthy Volunteers to Investigate How a New Drug for the Treatment of Parkinson's Disease, Dystonia and Amyotrophic Lateral Sclerosis Binds to Receptor Sites in the Brain.

Conditions

  • Healthy

Interventions

DRUG

HTL0014242

Solid suspension capsule

Sponsors & Collaborators

  • Nxera Pharma UK Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
23 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-29
Primary Completion
2021-06-23
Completion
2021-06-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04462263 on ClinicalTrials.gov